Kukje Pharma Co Ltd Cash Flow-to-Debt Ratio
Kukje Pharma Co Ltd cash flow-to-debt ratio. Kukje Pharma Co Ltd (002720) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of ₩4.99 Billion could theoretically repay 0% of its total liabilities (₩84.80 Billion) in one year. Check Kukje Pharma Co Ltd (002720) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kukje Pharma Co Ltd (2011–2024)
Cash flow-to-debt ratio of Kukje Pharma Co Ltd from 2011 to 2024. Historical debt coverage capacity for Kukje Pharma Co Ltd across 14 annual periods. Check Kukje Pharma Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Kukje Pharma Co Ltd Cash Flow-to-Debt Ratio by Year (2011–2024)
Kukje Pharma Co Ltd cash flow-to-debt ratio by year from 2011 to 2024. Year-by-year debt coverage analysis for Kukje Pharma Co Ltd. For the full cash flow conversion analysis, see 002720 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.05x | ₩3.94 Billion | ₩76.00 Billion | ▲ +13.6% |
| 2023 | 0.05x | ₩3.58 Billion | ₩78.31 Billion | ▼ -56.1% |
| 2022 | 0.10x | ₩6.50 Billion | ₩62.51 Billion | ▼ -22.8% |
| 2021 | 0.13x | ₩9.60 Billion | ₩71.20 Billion | ▲ +98.6% |
| 2020 | 0.07x | ₩5.10 Billion | ₩75.13 Billion | ▲ +38.7% |
| 2019 | 0.05x | ₩3.60 Billion | ₩73.64 Billion | ▼ -78.7% |
| 2018 | 0.23x | ₩13.25 Billion | ₩57.54 Billion | ▲ +1770.8% |
| 2017 | 0.01x | ₩786.10 Million | ₩63.87 Billion | ▼ -95.3% |
| 2016 | 0.26x | ₩16.10 Billion | ₩61.94 Billion | ▲ +448.9% |
| 2015 | -0.07x | ₩-5.08 Billion | ₩68.18 Billion | ▼ -8026.7% |
| 2014 | 0.00x | ₩-61.11 Million | ₩66.66 Billion | ▲ +98.8% |
| 2013 | -0.08x | ₩-4.60 Billion | ₩59.10 Billion | ▼ -393.2% |
| 2012 | 0.03x | ₩1.58 Billion | ₩59.57 Billion | ▼ -89.8% |
| 2011 | 0.26x | ₩17.39 Billion | ₩66.82 Billion | — |